Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Time to onset of disability progression was confirmed with four measures and time to requiring a wheelchair was also analyzed. At the study end, the percentage change from baseline was lower in those who initiated oc Relzumab early than in those initially receiving placebo. But progression remains an important unmet need in multiple sclerosis.
